Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973–977.
   PubMed Web of Science ®Google Scholar
• Hammwöhner M, Goette A. Will warfarin soon be passe? New approaches to stroke prevention in atrial fibrillation. J Cardiovasc Pharmacol. 2008;52:18–27.
   Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.
   PubMed Web of Science ®Google Scholar
• Blackshear JL, Safford RE. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card Electrophysiol Rev. 2003;7: 366–369.
   PubMedGoogle Scholar
• Hammwöhner M, D’Alessandro A, Wolfram O, Goette A. New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation. Curr Vasc Pharmacol. 2007;5:211–219.
   PubMed Web of Science ®Google Scholar
• Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265–325.
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011;8:502–512.
   PubMed Web of Science ®Google Scholar
• Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157–3163.
   PubMed Web of Science ®Google Scholar
• Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation. 1996;94: 2968–2974.
   PubMed Web of Science ®Google Scholar
• Bukowska A, Schild G, Keilhoff D, et al. Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. Exp Biol Med (Maywood). 2008;233:558–574.
   PubMedGoogle Scholar
• Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106:2854–2858.
   PubMed Web of Science ®Google Scholar
• Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004;43:2075–2082.
   PubMed Web of Science ®Google Scholar
• Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation. 1998;98: 1721–1727.
   PubMed Web of Science ®Google Scholar
• Goette A, Bukowska A, Lendeckel U, et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation. 2008;117:732–742.
   Web of Science ®Google Scholar
• Goette A, Ittenson A, Hoffmanns P, et al. Increased expression of P-selectin in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol. 2000;23:1872–1875.
   Web of Science ®Google Scholar
• Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35:1669–1677.
   PubMed Web of Science ®Google Scholar
• Hammwöhner M, Ittenson A, Dierkes J, et al. Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med (Maywood). 2007;232:581–589.
   PubMed Web of Science ®Google Scholar
• Hammwöhner M, Tautenhahn J, Kuester D, Goette A. Inadvertent catch of a factor VIII rich thrombus with a femoral sheath during cardiac catheterization. Int J Cardiol. 2008;130:e39–e41.
   Web of Science ®Google Scholar
• Kamiyama N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. Jpn Circ J. 1998;62:837–843.
   Google Scholar
• Kawamura T, Umemura T, Kanai A, et al. Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism. 2006;55: 461–466.
   Web of Science ®Google Scholar
• Noutsias M, Hohmann C, Pauschinger M, et al. sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. Int J Cardiol. 2006;91:153–161.
   Google Scholar
• Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005;97:629–636.
   PubMed Web of Science ®Google Scholar
• Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29: 106–112.
   PubMed Web of Science ®Google Scholar
• Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol. 2011;100:1029–1036.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Klerk CP, Meijers JC, Buller HR. The prognostic value of the D-dimer test in cancer patients treated with and without low- molecular-weight heparin. J Thromb Haemost. 2005;3:1531–1533.
   Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Bates SM. New anticoagulants.. J Thromb Haemost. 2005;3:1843–1853.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–1040.
   PubMed Web of Science ®Google Scholar
• Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure- based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45:1757–1766.
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162.
   PubMed Web of Science ®Google Scholar
• Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008;68: 1699–1709.
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98:333–338.
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost. 2007;5:1237–1242.
   Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–399.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47–59.
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555–563.
   PubMed Web of Science ®Google Scholar
• Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116–1127.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–268.
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–295.
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15 (Suppl 1):9S–16S.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59–68.
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103:572–585.
   PubMed Web of Science ®Google Scholar
• Lauer A, Cianchetti FA, Van Cott EM, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation. 2011;124:1654–1662.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2:1573–1580.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–111.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–956.
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419–1426.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805–810.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875–1876.
   PubMed Web of Science ®Google Scholar
• Diener HC, Connolly SJ, Ezekowitz MD, et al; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157–1163.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 1 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–2372.
   PubMed Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–136.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246–2253.
   PubMed Web of Science ®Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562–2570.
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144–1150.
   PubMed Web of Science ®Google Scholar
• Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27:74–90.
   Google Scholar
• Camm J, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. ROCKET AF trial. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation – regulatory considerations. NEngl J Med. 2011;365: 1557–1559.
   PubMed Web of Science ®Google Scholar
• Mega J, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011. doi: 10.1056/ NEJMoa1112277.
   Web of Science ®Google Scholar